ERBB2 and non-small cell lung carcinoma: A phase Ia/Ib trial (NCT04886804) is open to recruit approximately 96 patients worldwide who have HER2+ advanced solid tumor, including about 30 patients who have HER2 ex20ins mutant, pretreated, advanced NSCLC in the Ib arm.